Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell
      Original Publication: Oxford : Blackwell Scientific Publications
    • Subject Terms:
      Multiple Myeloma*/therapy ; Multiple Myeloma*/mortality ; Hematopoietic Stem Cell Transplantation*/methods ; Transplantation, Autologous*; Humans ; Aged ; Male ; Female ; Retrospective Studies ; Frailty ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Aged, 80 and over
    • Abstract:
      In patients with multiple myeloma (MM) not-eligible for autologous haematopoietic cell transplantation (autoHCT), a simplified frailty index (SFI) identifies frail patients at risk for poor outcomes, but data are limited for transplant-eligible patients. In this registry-based retrospective study, we used an adapted version of the SFI to determine the prevalence of frailty in patients ≥65 years of age with MM undergoing autoHCT. Out of 5563 patients, 37.9% of patients were classified as frail and although they had increased non-relapse mortality (NRM) and inferior overall survival, the NRM at 100 days remained low (<2%) compared with non-frail patients.
      (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
    • References:
      Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9:10003. https://doi.org/10.3390/medsci9010003.
      Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–1107. https://doi.org/10.1002/ajh.26590.
      Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132–147. https://doi.org/10.1056/NEJMoa2204925.
      Attal M, Lauwers‐Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–1320. https://doi.org/10.1056/NEJMoa1611750.
      Muchtar E, Dingli D, Kumar S, Buadi FK, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. 2016;51:1449–1455. https://doi.org/10.1038/bmt.2016.174.
      Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St. Martin A, Davila O, et al. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020;126:5077–5087. https://doi.org/10.1002/cncr.33171.
      Wildes TM, Tuchman SA, Klepin HD, Mikhael J, Trinkaus K, Stockerl‐Goldstein K, et al. Geriatric assessment in older adults with multiple myeloma. J Am Geriatr Soc. 2019;67:987–991. https://doi.org/10.1111/jgs.15715.
      Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant‐ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM‐020) trial. Leukemia. 2020;34:224–233. https://doi.org/10.1038/s41375‐019‐0539‐0.
      Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant‐ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36:1066–1077. https://doi.org/10.1038/s41375‐021‐01488‐8.
      Davis JA, Dima D, Ahmed N, DeJarnette S, McGuirk J, Jia X, et al. Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed/refractory multiple myeloma. Transplant Cell Ther. 2024;30:298–305. https://doi.org/10.1016/j.jtct.2023.12.015.
      Akhtar OS, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, et al. Real world outcomes of older adults and frail patients with relapse/refractory multiple myeloma receiving idecabtagene vicleucel. Transplant Cell Ther. 2024;30:S184–S185. https://doi.org/10.1016/j.jtct.2023.12.239.
      Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer. 2010;46:3175–3183. https://doi.org/10.1016/j.ejca.2010.06.126.
      Straka C, Schaefer‐Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, et al. Long‐term outcome of a prospective randomized trial comparing continuous lenalidomide/dexamethasone with lenalidomide/dexamethasone induction, MEL140 with autologous blood stem cell transplantation and single agent lenalidomide maintenance in patients of age 60–75 years with newly diagnosed multiple myeloma. Blood. 2022;140:287–288. https://doi.org/10.1182/blood‐2022‐159357.
      Boccadoro M, San‐Miguel J, Suzuki K, van de Donk NWCJ, Cook G, Jakubowiak A, et al. DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine/CARTITUDE‐6). Blood. 2022;140:4630–4632. https://doi.org/10.1182/blood‐2022‐157021.
      Manier S, Corre J, Hulin C, Laribi K, Araujo C, Pica GM, et al. A dexamethasone sparing‐regimen with daratumumab and lenalidomide in frail patients with newly‐diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017‐03 trial. Blood. 2022;140:1369–1370. https://doi.org/10.1182/blood‐2022‐159933.
      Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant‐ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235–2241. https://doi.org/10.1038/s41591‐024‐03050‐2.
      Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, et al. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol. 2019;10:479–485. https://doi.org/10.1016/j.jgo.2018.05.015.
      Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402–408.e1. https://doi.org/10.1016/j.bbmt.2013.12.557.
    • Grant Information:
      U24CA076518 National Cancer Institute (NCI); National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 Health Resources and Services Administration (HRSA); N00014-21-1-2954 Office of Naval Research; N00014-23-1-2057 Office of Naval Research
    • Contributed Indexing:
      Keywords: BMT; autologous stem cell transplantation; frailty; multiple myeloma; survival
    • Publication Date:
      Date Created: 20241013 Date Completed: 20241212 Latest Revision: 20241212
    • Publication Date:
      20241213
    • Accession Number:
      10.1111/bjh.19811
    • Accession Number:
      39396814